<DOC>
	<DOCNO>NCT00475644</DOCNO>
	<brief_summary>To evaluate antitumor activity , measure tumor response rate , enzastaurin patient Follicular Lymphoma ( FL ) .</brief_summary>
	<brief_title>A Study Enzastaurin Patients With Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<criteria>All patient must : 1 . Have histologically confirm diagnosis Grade 1 2 FL , accord World Health Organization classification ( Harris et al . 1999 ) , original time diagnosis . Pathology must confirm locally prior enrollment investigational site . 2 . Have Ann Arbor Stage III IV disease . 3 . Must chemonaive OR relapse disease receive one prior chemotherapy regimen . The chemotherapy must complete least 6 month prior first dose study treatment . Relapse one prior course singleagent rituximab treatment ( chemonaive setting ) also allow complete least 6 month prior first dose study treatment . 4 . Patients must require cytoreductive therapy least 3 month first dose study treatment , opinion investigator . 5 . Previous radiation therapy allow , limited must include whole pelvis radiation . Patients must recover toxic effect treatment prior study enrollment ( except alopecia ) . Prior radiotherapy must complete 30 day study entry . Lesions irradiate included site measurable disease unless clear tumor progression document lesion since end radiation therapy . Patients exclude study meet follow criterion : 1 . Are unable swallow tablet . 2 . Are unable discontinue use carbamazepine , phenobarbital , phenytoin . 3 . Are receive concurrent administration antitumor therapy . 4 . Are pregnant breastfeeding . 5 . Have serious concomitant systemic disorder ( include active bacterial , fungal , viral infection ) , opinion investigator , would compromise patient 's ability adhere protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>